532 related articles for article (PubMed ID: 20112369)
1. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
[TBL] [Abstract][Full Text] [Related]
2. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
3. KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.
McClintock-Treep SA; Horny HP; Sotlar K; Foucar MK; Reichard KK
J Clin Pathol; 2009 Dec; 62(12):1147-9. PubMed ID: 19729359
[TBL] [Abstract][Full Text] [Related]
4. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
[TBL] [Abstract][Full Text] [Related]
5. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
Horny HP; Sotlar K; Sperr WR; Valent P
J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
[TBL] [Abstract][Full Text] [Related]
6. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.
Wang SA; Hutchinson L; Tang G; Chen SS; Miron PM; Huh YO; Jones DM; Bueso-Ramos C; Verstovsek S; Medeiros LJ; Miranda RN
Am J Hematol; 2013 Mar; 88(3):219-24. PubMed ID: 23440662
[TBL] [Abstract][Full Text] [Related]
7. Mastocytosis.
Metcalfe DD
Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
[TBL] [Abstract][Full Text] [Related]
8. Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review.
Stoecker MM; Wang E
Arch Pathol Lab Med; 2012 Jul; 136(7):832-8. PubMed ID: 22742558
[TBL] [Abstract][Full Text] [Related]
9. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.
Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M
Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525
[TBL] [Abstract][Full Text] [Related]
10. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
11. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
Damaj G; Joris M; Chandesris O; Hanssens K; Soucie E; Canioni D; Kolb B; Durieu I; Gyan E; Livideanu C; Chèze S; Diouf M; Garidi R; Georgin-Lavialle S; Asnafi V; Lhermitte L; Lavigne C; Launay D; Arock M; Lortholary O; Dubreuil P; Hermine O
PLoS One; 2014; 9(1):e85362. PubMed ID: 24465546
[TBL] [Abstract][Full Text] [Related]
12. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
[TBL] [Abstract][Full Text] [Related]
13. Systemic mastocytosis (SM) and associated malignant bone marrow histiocytosis - a hitherto undescribed form of SM-AHNMD.
Rudzki Z; Sotlar K; Kudela A; Starzak-Gwóźdź J; Horny HP
Pol J Pathol; 2011; 62(2):101-4. PubMed ID: 21866466
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
[TBL] [Abstract][Full Text] [Related]
15. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
16. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
Pullarkat V; Bedell V; Kim Y; Bhatia R; Nakamura R; Forman S; Sun J; Senitzer D; Slovak ML
Leuk Res; 2007 Feb; 31(2):261-5. PubMed ID: 16876862
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
[TBL] [Abstract][Full Text] [Related]
18. Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease.
Hauswirth AW; Födinger M; Fritz M; Müllauer L; Simonitsch-Klupp I; Streubel B; Chott A; Sperr WR; Jäger U; Valent P
Hum Pathol; 2008 Jun; 39(6):917-24. PubMed ID: 18448146
[TBL] [Abstract][Full Text] [Related]
19. Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm.
Gülen T; Sander B; Nilsson G; Palmblad J; Sotlar K; Horny HP; Hägglund H
Med Oncol; 2012 Dec; 29(5):3540-6. PubMed ID: 22661384
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]